# ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

> **NCT01184300** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 200 (actual)

## Conditions studied

- Stable Coronary Artery Disease
- Acute Coronary Syndrome
- Percutaneous Coronary Intervention

## Interventions

- **GENETIC:** Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers

## Key facts

- **NCT ID:** NCT01184300
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2011-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01184300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01184300, "ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01184300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*